<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817843</url>
  </required_header>
  <id_info>
    <org_study_id>Vasc-UMCU-10B</org_study_id>
    <secondary_id>2008-003908-61</secondary_id>
    <nct_id>NCT00817843</nct_id>
  </id_info>
  <brief_title>The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study</brief_title>
  <acronym>PANACEA</acronym>
  <official_title>Multicenter,Double Blind,Randomized, 2-period, Crossover Study to Compare Ezetimibe/Simvastatin (10mg/10 mg) Combination Tablet Versus Simvastatin 80mg Tablet on Postprandial Arterial Endothelial Function in Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>dr.Frank L.J. Visseren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether low-dose simvastatin in combination with
      ezetimibe in comparison to high-dose simvastatin alone, has a beneficial effect on the
      function of the endothelium after an oral fat load in patients with metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome is defined as a group of cardiovascular risk factors and is mainly driven
      by the epidemic of obesity. High blood lipid levels after a meal may be an important risk
      factor for cardiovascular disease. In this study we will investigate whether simvastatin in
      combination with ezetimibe vs. simvastatin alone, has a beneficial effect on the lipid levels
      after a meal, but more importantly, whether we can measure a difference in function of the
      endothelium. In a small pilot study we already found that the combination had a beneficial
      effect in comparison with simvastatin alone. Now we want to solidify these findings in a
      larger study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Difference in (Postprandial-Fasting) FMD</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>A comparison of the postprandial minus fasting change in FMD under treatment with simvastatin 80 mg versus simvastatin 10/10 mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Endopat Measurement</measure>
    <time_frame>after 6 weeks of treatment (crossover)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preprandial Endothelial Function Measured by FMD</measure>
    <time_frame>after 6 weeks of treatment (crossover)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preprandial Endopat Measurement</measure>
    <time_frame>after 6 weeks of treatment (crossover)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>First Simva 80mg then Simvai/Eze10/10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 6 weeks of Simvastatin 80mg, then 6 weeks of Simvastatin/Ezetimibe 10/10mg after 6 weeks of placebo washout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Simva/Eze 10/10mg then Simva 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 6 weeks of Simvastatin/Ezetimibe 10/10mg, then 6 weeks of Simvastatin 80mg after 6 weeks of placebo washout</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>6 weeks of treatment with simvastatin 80 mg</description>
    <arm_group_label>First Simva 80mg then Simvai/Eze10/10mg</arm_group_label>
    <arm_group_label>First Simva/Eze 10/10mg then Simva 80mg</arm_group_label>
    <other_name>Simvastatin (Zocor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin/Ezetimibe</intervention_name>
    <description>6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination</description>
    <arm_group_label>First Simva 80mg then Simvai/Eze10/10mg</arm_group_label>
    <arm_group_label>First Simva/Eze 10/10mg then Simva 80mg</arm_group_label>
    <other_name>Simvastatin/Ezetimibe (Zetia)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Patient has a diagnosis of metabolic syndrome according to the modified 2005 AHA/NHLBI
             Scientific Statement with at least:

             - Abdominal obesity defined as:

             *Males: waist circumference &gt;102cm

               -  Females: waist circumference &gt;88cm and two of the following 4 other criteria:

                  - Triglycerides&gt;150 mg/dL

                  - HDL Cholesterol

               -  Males: HDL-C&lt;40 mg/dL

               -  Females:HDL-C&lt;50 mg/dL - Blood pressure

               -  Systolic Blood Pressure ≥130 mmHg or

               -  Diastolic Blood Pressure ≥85 mmHg

                    -  Fasting glucose ≥ 100 mg/dL

          2. Patient understands the study procedures, alternative treatments available, and risks
             involved with the study, and voluntarily agrees to participate by giving written
             informed consent.

          3. Patient is a male or female of 18-79 years of age on the day of signing informed
             consent.

          4. Patient is a non-smoker.

          5. Patient is willing to maintain a stable diet for the duration of the study.

          6. Patient is a postmenopausal female who is not receiving hormone therapy (including
             cyclic and non-cyclical hormone replacement therapy or any estrogen
             antagonist/agonist). Postmenopausal status is defined as (1) no menses for ≥1 year but
             &lt;3 years and confirmed by FSH levels elevated into the postmenopausal range (as
             defined by the designated laboratory) or (2) no menses for at least 3 years.

          7. Patient is naïve to lipid-lowering therapy. Naïve is defined as not being treated with
             a statin, a fibrate or ezetimibe for 3 months before Visit 1 (Week -2)

          8. Patient has a baseline fasting LDL-C level of ≥ 100 mg/dL and &lt; 220 mg/dL, and TG
             level &lt; 400 mg/dL.

        EXCLUSION CRITERIA:

          1. Patient has a BMI &gt; 35.

          2. Patient has hypersensitivity or intolerance to ezetimibe or simvastatin or any
             component of these medications, or to latex.

          3. Patient routinely consumes more than 14 alcoholic drinks per week.

          4. Patient is currently participating or has participated in a study with an
             investigational compound or device within 30 days of signing informed consent.

          5. Patient has a smoking history &gt; 10 pack-years (1 pack-year = at least 20 cigarettes
             per day for a year) OR patient who has smoked within 3 months prior to Visit 1 (Week
             -2).

          6. Patient has exclusionary laboratory values at Visit 1 (Week -2) as listed in the table
             below:

             liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase
             [AST]) &gt; 1.5 X ULN with no active liver disease Serum glucose &gt; 7.0 mmol/L Creatine
             kinase(CK)&gt; 2 X ULN Albumin:creatinine ratio &gt; 34 TSH &lt;0.3 mcIU/mL or &gt; 5.0 mcIU/mL

          7. Patient has a history or current evidence of any condition, therapy, lab abnormality
             or other circumstance that might confound the results of the study, or interfere with
             the patient's participation for the full duration of the study, such that it is not in
             the best interest of the patient to participate.

          8. It is not possible to obtain a FMD measurement of sufficient quality at screening
             (Visit 1)

          9. Patient has congestive heart failure, atherosclerotic vascular disease or acute or
             chronic coronary heart disease.

        13. Patient has had a partial ileal bypass, gastric bypass, gastric banding, celiac disease
        or other significant intestinal malabsorption.

        15. Patient has untreated and uncontrolled hypertension with systolic blood pressure &gt;160
        mm Hg or diastolic &gt;100 mm Hg at Visit 1 (Week -2). (Patients with untreated hypertension
        and with office BP at Visit 1 and Visit 2 averaging 160/100 or less can be enrolled).
        Patients using blood pressure-lowering medication are excluded.

        16. Patient has estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73 m2 based on
        the 4-variable MDRD

        17. Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids
        or lipoproteins at Visit 1 (Week -2).

        18. Patient has diabetes mellitus defined as a history of diabetes or fasting serum glucose
        &gt; 126 mg/dL.

        For the full exclusion criteria, please check the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank LJ Visseren, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1005 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Research Center Hoorn</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Medicine UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tweesteden Ziekenhuis</name>
      <address>
        <city>Waalwijk</city>
        <zip>5141 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>E-25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol. 2008 Aug;52(2):145-50. doi: 10.1097/FJC.0b013e31817ffe76.</citation>
    <PMID>18670365</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <results_first_submitted>June 18, 2012</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2013</results_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>dr.Frank L.J. Visseren</investigator_full_name>
    <investigator_title>Professor F.L.J. Visseren, MD PhD, head of department of Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Postprandial hypertriglyceridemia</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Flow mediated dilatation</keyword>
  <keyword>EndoPAT</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Ezetimibe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between and patients were screened of which subjects were randomized in the following centers UMC Utrecht, Utrecht, the Netherlands AMC, Amsterdam, the Netherlands Vascular Research Center, Hoorn, the Netherlands Tweesteden Ziekenhuis, Waalwijk, the Netherlands Hospital Arnau de Vilanova, Lleida, Spain</recruitment_details>
      <pre_assignment_details>Prior to randomization subjects were given a 2 week placebo controled run-in phase to test for adequate compliance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin 80mg First, Then Simvastatin/Ezetimibe 10/10mg</title>
          <description>First 6 weeks of treatment with simvastatin 80 mg with placebo, followed by 6 weeks of placebo controlled washout and 6 weeks of simvastatin/ezetimibe 10/10 mg combination and placebo</description>
        </group>
        <group group_id="P2">
          <title>Simvastatin/Ezetimibe 10/10mg First, Then Simvastatin 80mg</title>
          <description>First 6 weeks of treatment with simvastatin/ezetimibe 10/10 mg combination with placebo, followed by 6 weeks of placebo controlled washout and 6 weeks of simvastatin 80 mg and placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Period (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42">All patients with &gt;=1 postrandomization dose and measurement were analyzed</participants>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Period (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41">All patients with &gt;=1 postrandomization dose and measurement were analyzed</participants>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin 80mg or Simvastatin/Ezetimibe 10/10mg</title>
          <description>All patients were randomized to receive either Simvastatin 80mg or Simvastatin/Ezetimibe 10/10mg during this period</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Endopat Measurement</title>
        <time_frame>after 6 weeks of treatment (crossover)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preprandial Endothelial Function Measured by FMD</title>
        <time_frame>after 6 weeks of treatment (crossover)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preprandial Endopat Measurement</title>
        <time_frame>after 6 weeks of treatment (crossover)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Difference in (Postprandial-Fasting) FMD</title>
        <description>A comparison of the postprandial minus fasting change in FMD under treatment with simvastatin 80 mg versus simvastatin 10/10 mg</description>
        <time_frame>After 6 weeks of treatment</time_frame>
        <population>Analyses were performed in randomized patients who received ≥1 dose of study treatment and who had a post-randomization analysis measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 80 mg</title>
            <description>6 weeks of treatment with simvastatin 80 mg</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 10 mg / Ezetimibe 10 mg</title>
            <description>6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Difference in (Postprandial-Fasting) FMD</title>
          <description>A comparison of the postprandial minus fasting change in FMD under treatment with simvastatin 80 mg versus simvastatin 10/10 mg</description>
          <population>Analyses were performed in randomized patients who received ≥1 dose of study treatment and who had a post-randomization analysis measurement</population>
          <units>% (change FMD)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.210"/>
                    <measurement group_id="O2" value="-0.43" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Between treatment difference in the change in FMD from the fasting to the post-fat load state.
Null hypothesis was that combination therapy (simvastatin/ezetimibe) would protect the FMD in the post-fat load phase and would therefore be associated with a smaller drop in FMD
Power calculation was based on the results from a pilot study. To detect a 1.0% difference between treatments with a SD of 2.7% and a power of 90% (alfa 0.05, two tailed) 80 evaluable patients were needed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.295</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin 80mg or Simvastatin/Ezetimibe 10/10mg</title>
          <description>All patients were randomized to receive either Simvastatin 80mg or Simvastatin/Ezetimibe 10/10mg during this period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>During placebo washout phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>During placebo washout</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation is that the study was conducted in obese patients with the metabolic syndrome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor F.L.J. Visseren, MD PhD</name_or_title>
      <organization>UMC Utrecht</organization>
      <phone>0031-88-7555555</phone>
      <email>f.l.j.visseren@umcutrecht.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

